Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Study reveals immune aging differs significantly between men and women

Statistics show clear differences in the population's immune system according to sex: men are more susceptible to infections and cancers, while women have stronger immune responses, which translate, for example, into better responses to vaccines.

11 Apr 2026

CAR T therapy induces remission in multiple autoimmune diseases

For the first time, scientists have used a cutting-edge cell therapy called CAR-T to treat a patient with three different life-threatening autoimmune diseases that had resisted years of treatment.

9 Apr 2026

OICR funds four Ontario teams to develop next-generation cancer therapies

Better cancer care depends on better treatment options. That's why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumors, have reduced side effects, and make cancer less likely to return.

9 Apr 2026

New clinical guidelines address blood clot prevention in pediatric patients

The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) released comprehensive clinical practice guidelines on anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism (VTE).

8 Apr 2026

Future CAR therapy expands beyond T cells to treat diverse diseases

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

8 Apr 2026

CIPHER-seq technology reveals how immune cells communicate during treatment

A new single-cell technology is giving scientists their clearest view yet of immune cell behavior-capturing not just genetic intent but real-time activity.

8 Apr 2026

Study finds increasing rates of therapy-related acute myeloid leukemia

Some therapies used to treat cancer may increase the risk of later developing cancers that affect the blood.

6 Apr 2026

Lung cancer scans can reveal signs of other undiagnosed cancers

When doctors review diagnostic medical scans for lung cancer, they sometimes spot abnormalities unrelated to the lungs.

31 Mar 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Study reveals CAR T approach for hard-to-treat solid tumors

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma.

30 Mar 2026

Immune cells use neurotransmitters to regulate health and disease

The article, titled "Emerging roles of immune cell-derived neurotransmitters in immunity and disease," published on March 17, 2026, in Immunity & Inflammation, provides a timely and authoritative review of how innate and adaptive immune cells-including macrophages, dendritic cells, natural killer cells, T cells, and B cells-produce and respond to classic neurotransmitters.

25 Mar 2026

New approach helps immune cells find and attack solid tumors

A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine researchers.

24 Mar 2026

Study reveals genetic impact of Agent Orange on bone marrow cancers

More than 50 years after Agent Orange was used in Vietnam, a new national study published online ahead of print in Blood Advances highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes (MDS), a group of bone marrow cancers that can progress to acute leukemia.

23 Mar 2026

Cancer cells rely on glutathione as fuel for growth

Researchers discovered an antioxidant, glutathione, that cancer cells appear to be "addicted to" as fuel, opening new pathways for investigation and a potential drug that can restrict the way tumors use this nutrient.

18 Mar 2026

New CAR-T cell therapy shows promise for treating osteosarcoma

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has puzzled medical researchers for 40 years.

17 Mar 2026

New method creates longer lasting CAR T cells for cancer therapy

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into patients to fight cancer and HIV, addressing a major limitation of current treatments.

13 Mar 2026

Fertility treatments linked to small increases in some cancers

Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns with the general female population.

13 Mar 2026

Simplified nanoparticles "educate" the immune system to find and destroy disease-causing cells

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout the body.

11 Mar 2026

$Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia$

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them.

9 Mar 2026

Ketone body can strengthen the fitness and antitumor activity of CAR T cells

A naturally occurring byproduct of liver metabolism–the ketone body, β-hydroxybutyrate (BHB)–can strengthen the fitness and antitumor activity of CAR T cells.

6 Mar 2026